Back to top
more

Ritter Pharmaceuticals, Inc. (RTTR)

(Delayed Data from NSDQ)

$1.72 USD

1.72
12,989

+0.05 (2.99%)

Updated Oct 18, 2018 04:00 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
25.68%
18.56%
10.1%
5.5%
2.33%
10.82%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

D Value | B Growth | B Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Brokerage Reports

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for RTTR

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

0 items in cart

Ritter Pharmaceuticals, Inc. [RTTR]

Reports for Purchase

Showing records 1 - 20 ( 35 total )

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1

10/16/2018

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for RTTR

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 2

08/16/2018

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 3

08/15/2018

Company Report

Pages: 8

2Q18 Recap - Trial Underway, Data Likely in 2H19

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 4

08/15/2018

Company Report

Pages: 4

2Q 2018 Financial Results Reported; Wider-Than- Projected Net Loss as Pivotal Trial Advances; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 5

06/28/2018

Company Report

Pages: 5

First RP-G28 Phase 3 Trial Kicks Off; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 6

06/06/2018

Company Report

Pages: 5

RP-G28 Clinical Program Showcased at Digestive Disease Week; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 7

05/29/2018

Company Report

Pages: 4

Respected Biopharma Executive Appointed as New Chief Financial Officer; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 8

05/29/2018

Company Report

Pages: 4

1Q 2018 Financial Results Reported; RP-G28 Phase 2b Data Presentation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 9

05/17/2018

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 10

05/16/2018

Company Report

Pages: 8

1Q18 Recap - P3 Trial Start Imminent

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 11

03/20/2018

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 12

03/19/2018

Company Report

Pages: 8

Q17 Recap - P3 Patient Screening to Start in 2Q18

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 13

03/12/2018

Company Report

Pages: 4

Phase 2b Microbiome Data Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 14

03/05/2018

Company Report

Pages: 4

1-for-10 Reverse Stock Split Authorized; Adjusting Price Target to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 15

11/01/2017

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 16

10/31/2017

Company Report

Pages: 8

3Q17 Recap - Cash Replenished; Trial to Start in 1H18

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 17

10/24/2017

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 18

10/23/2017

Company Report

Pages: 7

Version 2.0 Ready for Launch

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 19

10/23/2017

Company Report

Pages: 13

RP-G28 Clinical Development Pathway Clarified; Financing Complete; Reducing Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 50.00

Research Provided by a Third Party

Company: Ritter Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 20

08/08/2017

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party